171 related articles for article (PubMed ID: 12486406)
1. Ethanol enhances the inhibitory effect of an oral GPIIb/IIIa antagonist on human platelet function.
Rand ML; Jakubowski JA; Fisher MJ; Chahil A; Kinlough-Rathbone RL; Packham MA
J Lab Clin Med; 2002 Dec; 140(6):391-7. PubMed ID: 12486406
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
3. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
4. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
[TBL] [Abstract][Full Text] [Related]
5. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M
Acta Pol Pharm; 2009; 66(3):235-42. PubMed ID: 19645323
[TBL] [Abstract][Full Text] [Related]
6. Platelet alpha-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist.
Ogawa T; Sugidachi A; Otsuguro K; Isobe T; Asai F
Biochem Pharmacol; 2002 May; 63(10):1911-8. PubMed ID: 12034376
[TBL] [Abstract][Full Text] [Related]
7. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
[TBL] [Abstract][Full Text] [Related]
9. Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists.
Rebello SS; Huang J; Faul JD; Lucchesi BR
J Thromb Thrombolysis; 2000 Jan; 9(1):23-8. PubMed ID: 10590185
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
[TBL] [Abstract][Full Text] [Related]
11. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
12. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
13. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor.
Barre DE
Thromb Res; 2007; 119(5):601-7. PubMed ID: 16860375
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation.
Quinton TM; Kim S; Dangelmaier C; Dorsam RT; Jin J; Daniel JL; Kunapuli SP
Biochem J; 2002 Dec; 368(Pt 2):535-43. PubMed ID: 12215172
[TBL] [Abstract][Full Text] [Related]
15. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
17. Effects of ethanol on pathways of platelet aggregation in vitro.
Rand ML; Packham MA; Kinlough-Rathbone RL; Fraser Mustard J
Thromb Haemost; 1988 Jun; 59(3):383-7. PubMed ID: 3142075
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
Li YF; Spencer FA; Becker RC
Am Heart J; 2001 Aug; 142(2):204-10. PubMed ID: 11479455
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
20. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.
Dickfeld T; Ruf A; Pogatsa-Murray G; Müller I; Engelmann B; Taubitz W; Fischer J; Meier O; Gawaz M
Thromb Res; 2001 Jan; 101(2):53-64. PubMed ID: 11342206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
